CANADA LIFE ASSURANCE Co Sells 1,909 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

CANADA LIFE ASSURANCE Co lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 66,071 shares of the company’s stock after selling 1,909 shares during the period. CANADA LIFE ASSURANCE Co owned approximately 0.08% of IDEXX Laboratories worth $35,689,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of IDXX. Valley National Advisers Inc. increased its holdings in shares of IDEXX Laboratories by 84.6% in the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock worth $26,000 after buying an additional 22 shares during the last quarter. Riverview Trust Co purchased a new stake in IDEXX Laboratories during the first quarter valued at $26,000. DSM Capital Partners LLC purchased a new stake in IDEXX Laboratories during the fourth quarter valued at $33,000. Venturi Wealth Management LLC raised its stake in shares of IDEXX Laboratories by 226.3% in the fourth quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock valued at $34,000 after acquiring an additional 43 shares during the period. Finally, Private Wealth Management Group LLC bought a new position in IDEXX Laboratories during the 4th quarter worth about $34,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on IDXX shares. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. BTIG Research started coverage on shares of IDEXX Laboratories in a research note on Thursday. They issued a “buy” rating and a $580.00 price target on the stock. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Barclays lowered their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Finally, Morgan Stanley cut their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $585.89.

Insiders Place Their Bets

In related news, Director Bruce L. Claflin sold 200 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the completion of the transaction, the director now owns 161 shares in the company, valued at approximately $87,068.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX traded up $1.52 during mid-day trading on Thursday, hitting $472.86. The stock had a trading volume of 328,258 shares, compared to its average volume of 474,423. The company has a market cap of $39.05 billion, a PE ratio of 45.63, a PEG ratio of 3.85 and a beta of 1.32. The company’s fifty day simple moving average is $496.49 and its two-hundred day simple moving average is $518.26. The company has a quick ratio of 1.16, a current ratio of 1.57 and a debt-to-equity ratio of 0.40. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.13. The company had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.